An Attempt to Quantitate “Value” In Medical Oncologic Therapy

Objective We wanted to examine the incremental cost-effective ratio (ICER) for a variety of Food and Drug Administration (FDA) approved oncology drugs in the adjuvant or curative setting to determine the value provided. Design We examined the annualized incremental drug costs of a variety of FDA app...

Descripción completa

Detalles Bibliográficos
Autores principales: Hancock, Christie, Green, Linda, Lestingi, Timothy, Bitran, MD, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092191/
https://www.ncbi.nlm.nih.gov/pubmed/30116683
http://dx.doi.org/10.7759/cureus.2810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092191/
https://www.ncbi.nlm.nih.gov/pubmed/30116683
http://dx.doi.org/10.7759/cureus.2810

Ejemplares similares